Literature DB >> 26448667

Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.

Betsy Karli1, Billie Bartel2, Rachel Pavelko3.   

Abstract

Factor Xa (fXa) inhibitors are becoming more common in clinical practice due to a variety of reasons. Unfortunately, limited data are currently available on the safe and efficacious reversal of these agents. This series presents 3 patient cases of intracranial hemorrhage and illustrates the observed effect of different methodologies undertaken in an attempt to reverse the fXa inhibitors implicated. Additionally, a brief review of the current available literature in reversal strategies is provided. The appropriate reversal for fXa inhibitors at this time is unknown. The cases described indicate that the administration of fresh frozen plasma and 4-factor prothrombin complex concentrate may provide minimal benefit in reversing the coagulation abnormalities caused by fXa inhibitors. However, in a life-threatening situation, the addition of these agents should be considered to prevent further progression of the bleed.

Entities:  

Year:  2015        PMID: 26448667      PMCID: PMC4589860          DOI: 10.1310/hpj5007-569

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  26 in total

Review 1.  Reversal of anticoagulants: an overview of current developments.

Authors:  Andreas Greinacher; Thomas Thiele; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Outcome following intracranial hemorrhage associated with novel oral anticoagulants.

Authors:  Manish K Kasliwal; Nicholas G Panos; Lorenzo F Munoz; Roham Moftakhar; Demetrius K Lopes; Richard W Byrne
Journal:  J Clin Neurosci       Date:  2014-07-25       Impact factor: 1.961

Review 4.  Monitoring and reversal strategies for new oral anticoagulants.

Authors:  Sophie Vanden Daelen; Marijke Peetermans; Thomas Vanassche; Peter Verhamme; Erik Vandermeulen
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-11-28

5.  Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

Authors:  Anne Godier; Anastasia Miclot; Bernard Le Bonniec; Marion Durand; Anne-Marie Fischer; Joseph Emmerich; Catherine Marchand-Leroux; Thomas Lecompte; Charles-Marc Samama
Journal:  Anesthesiology       Date:  2012-01       Impact factor: 7.892

Review 6.  Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Authors:  Marta A Miyares; Kyle Davis
Journal:  Am J Health Syst Pharm       Date:  2012-09-01       Impact factor: 2.637

7.  Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.

Authors:  Eva Herzog; Franz Kaspereit; Wilfried Krege; Jochen Mueller-Cohrs; Baerbel Doerr; Peter Niebl; Gerhard Dickneite
Journal:  Thromb Res       Date:  2015-01-09       Impact factor: 3.944

8.  Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Authors:  Elaine M Hylek; Claes Held; John H Alexander; Renato D Lopes; Raffaele De Caterina; Daniel M Wojdyla; Kurt Huber; Petr Jansky; Philippe Gabriel Steg; Michael Hanna; Laine Thomas; Lars Wallentin; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2014-03-19       Impact factor: 24.094

9.  Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.

Authors:  Wei Zhou; Markus Zorn; Peter Nawroth; Ulf Bütehorn; Elisabeth Perzborn; Stefan Heitmeier; Roland Veltkamp
Journal:  Stroke       Date:  2013-01-22       Impact factor: 7.914

10.  Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

Authors:  Xiaoli Wang; Sabiha Mondal; Jessie Wang; Giridhar Tirucherai; Donglu Zhang; Rebecca A Boyd; Charles Frost
Journal:  Am J Cardiovasc Drugs       Date:  2014-04       Impact factor: 3.571

View more
  1 in total

Review 1.  Apixaban-induced subdural bleeding: case presentation and literature review.

Authors:  Eman Alayad; Sami Khairy; Ahmed Aloraidi
Journal:  BMJ Case Rep       Date:  2018-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.